PEBC MCQ Practice Questions by Topic

Diagnosis thresholds, first-line and add-on antihypertensives, special populations, home BP, statin intensity and LDL-C/non-HDL-C targets, ezetimibe and PCSK9 inhibitors, cardiovascular risk assessment (Hypertension Canada; CCS dyslipidemia).

HFrEF foundational therapy, AF rate/rhythm control and stroke prevention (CHADS-65), stable angina and ACS secondary prevention, antiplatelet therapy, VTE treatment and prophylaxis, warfarin and DOAC management (CCS guidelines).

Type 1 and type 2 diabetes (Diabetes Canada), hypoglycemia, sick-day medications, insulin, thyroid disease, osteoporosis (Osteoporosis Canada), contraception, menopause hormone therapy.

Asthma control criteria and stepwise therapy (CTS/GINA), COPD therapy by symptoms and exacerbation risk (CTS), inhaler technique, smoking cessation pharmacotherapy, allergic rhinitis.

UTI, pneumonia, skin and soft-tissue infections, C. difficile, STIs, H. pylori, antimicrobial selection and allergy assessment, HIV and hepatitis basics, vaccines and the Canadian Immunization Guide (NACI).

Depression and anxiety (CANMAT), bipolar disorder, schizophrenia and antipsychotic monitoring, ADHD, insomnia, substance use and opioid agonist therapy, epilepsy, Parkinson disease, dementia, migraine.

GERD and peptic ulcer disease, IBD, IBS, constipation and diarrhea, nausea and vomiting, chronic kidney disease and renal dose adjustment, electrolyte disorders, liver disease and drug-induced liver injury.

Acute and chronic pain, opioid selection, conversion and safety (Canadian opioid guideline), NSAID risk, osteoarthritis, rheumatoid arthritis and DMARD monitoring, gout.

Nonprescription therapy and referral: cough and cold, allergic conjunctivitis, dermatology (acne, dermatitis, fungal, lice), GI self-care, emergency contraception, vaginal candidiasis, pediatric fever, natural health products, minor ailment assessment.

Pediatric dosing and care, older adults and deprescribing (Beers/STOPP), pregnancy and lactation, oncology supportive care, BPH and urinary incontinence, ophthalmic and dermatologic prescription therapy, transplant basics.

Validity of prescriptions, drug schedules (NAPRA NDS and federal), narcotic and controlled drug prescriptions, refills, transfers, drug interaction and dose checks at intake, labelling and auxiliary labels, release and counselling at pickup, compliance packaging.

Dose by weight and BSA, pediatric doses, IV infusion rates, concentrations and dilutions, mEq and mmol, creatinine clearance (Cockcroft-Gault), aminoglycoside and vancomycin basics, days' supply, compounding quantities, opioid conversions.

NAPRA non-sterile and sterile compounding standards, hazardous drugs, beyond-use dates, storage and cold chain, product verification, inventory, recalls, narcotic counts and loss or theft reporting, drug shortages.

Study designs, bias, biostatistics (NNT, NNH, RR, OR, confidence intervals, p-values, type I and II error), pharmacoeconomics, critical appraisal, drug information sources, applying evidence to an individual patient.

Patient-centred communication, shared decision-making, motivational interviewing, health literacy, interprofessional collaboration, handling disagreement with prescribers, documentation and pharmacy records.

Health promotion and disease prevention, screening, antimicrobial stewardship, vaccination programs, harm reduction and naloxone, population health and health equity.

Food and Drugs Act and Regulations, Controlled Drugs and Substances Act, Narcotic Control Regulations, Benzodiazepines and Other Targeted Substances Regulations, NAPRA National Drug Schedules, Cannabis Act, privacy law, scope of practice, MAID, adverse reaction reporting (Vanessa's Law).

Ethical principles and dilemmas, conscientious objection, conflicts of interest, confidentiality, equity, diversity and inclusion, Truth and Reconciliation, medication incident reporting and analysis (ISMP Canada), high-alert drugs, continuous quality improvement.